Category: Allergan Inc.Syndicate content

UPDATE: Valeant ready to raise Allergan bid to at least $200/share

October 27, 2014 by MassDevice

Valeant Pharmaceuticals says it's ready to up the ante in its hostile takeover bid for Allergan.

UPDATE: Valeant ready to raise Allergan bid to at least $200/share

JNJ/Synthes integration continues to bring hefty charges | The week in medtech M&A

October 22, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: JNJ continues to pay hefty integration charges on Synthes deal; Stryker: Mako sales not as strong as we hoped; ConvaTec owners appoint banks to explore sale: sources; BD buys Irish next-gen sequencing startup GenCell Biosystems; Valeant says may raise Allergan bid; beats on profit

JNJ continues to pay hefty integration charges on Synthes deal

October 16, 2014 by Brian Johnson

Allergan says it stands by statements on Valeant

October 21, 2014 by MassDevice

Allergan says there's no evidence to back claims by hostile suitors Valeant Pharmaceuticals and hedge mogul William Ackman's Pershing Square Capital Management that Allergan CEO David Pyott led a smear campaign against them.

Allergan says it stands by statements on Valeant

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Valeant says may raise Allergan bid; beats on profit

October 20, 2014 by MassDevice

Valeant Pharmaceuticals says it might up the ante in its hostile takeover bid for Allergan as it reports higher-than-forecast profits for its 3rd quarter.

Valeant says may raise Allergan bid; beats on profit

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtronic reveals leadership team after mega-merger with Covidien | The week in medtech M&A

October 15, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Medtronic announces leadership roster for post-Covidien merger; Allergan raises outlook; says Valeant offer undervalues company; EuroZone anti-trust regulators to rule next month on $43B Covidien buy; Steris to buy UK's Synergy Health, tax savings eyed; Bioventus bolsters bone healing lineup

Medtronic announces leadership roster for post-Covidien merger

October 10, 2014 by Brad Perriello

Allergan raises outlook; says Valeant offer undervalues company

October 10, 2014 by MassDevice

Irvine, Calif.-based Allergan boosted 3rd quarter profit estimates, said Valeant's offer is weak

Allergan caves to shareholder meeting after Valeant, Ackman rally support

Exclusive: Actavis plans new merger approach for Allergan - sources

October 8, 2014 by MassDevice

Actavis aims to head Valeant Pharmaceuticals off at the pass with a competing bid to acquire Allergan, people familiar with the matter tell Reuters.

Exclusive: Actavis plans new merger approach for Allergan - sources

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp